Literature DB >> 8801596

Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats.

M Fujikawa1, M Nagashima, T Inoue, K Yamada, T Furukawa.   

Abstract

The present experiments were performed to examine the behavioral effects of OPC-14597, which acts on dopamine receptors in rats. OPC-14597 administered subcutaneously (SC) at doses of 0.1-5 mg/kg elicited yawning, as did OPC-4392 (0.5-2 mg/kg, SC) and (-)-3-PPP (2.5-10 mg/kg, SC). These yawning responses were blocked by intraperitoneal (IP) pretreatment with haloperidol (0.5 mg/kg) but were increased by pindolol (20 mg/kg, IP) or reserpine (5 mg/kg, IP), which per se did not elicit yawning. The yawning induced by talipexole, a selective dopamine D2 receptor agonist, was inhibited by OPC-14597 (0.5-5 mg/kg, SC) and (-)-3-PPP (10 mg/kg, SC). Apomorphine (0.5 mg/kg, SC), a dopamine D1/D2 receptor agonist, elicited stereotypy such as sniffing and licking but OPC-14597 (5-20 mg/kg, SC) did not induce this behavior. The stereotypy induced by apomorphine was inhibited not only by haloperidol (0.5 mg/kg, IP) and (-)-3-PPP (10 mg/kg, SC) but also by OPC-14597 (5-20 mg/kg, SC), without being affected by OPC-4392 (2 mg/kg, SC). In 6-hydroxydopamine (6-OHDA)-treated rats, apomorphine (0.5 mg/kg, SC) elicited rotation behavior whereas OPC-14597, OPC-4392 and (-)-3-PPP did not produce this behavior. These findings suggest that OPC-14597 provokes yawning without causing stereotypy and rotation but markedly antagonizes the talipexole-induced yawning and apomorphine-induced stereotypy, and that OPC-14597 thus exerts partial agonistic effects on yawning behavior but antagonistic effects on stereotypy in rats.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8801596     DOI: 10.1016/0091-3057(95)02096-9

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  9 in total

1.  Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.

Authors:  Beryl Koener; Stéphanie Goursaud; Morgane Van De Stadt; André-Guilhem Calas; Anne P Jeanjean; Jean-Marie Maloteaux; Emmanuel Hermans
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01       Impact factor: 3.000

2.  Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.

Authors:  Chiara Rapinesi; Georgios D Kotzalidis; Lorenzo Mazzarini; Roberto Brugnoli; Stefano Ferracuti; Sergio De Filippis; Ilaria Cuomo; Gloria Giordano; Antonio Del Casale; Gloria Angeletti; Gabriele Sani; Paolo Girardi
Journal:  Clin Drug Investig       Date:  2019-08       Impact factor: 2.859

Review 3.  Aripiprazole.

Authors:  Jane K McGavin; Karen L Goa
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys.

Authors:  Paul W Czoty; H Donald Gage; Pradeep K Garg; Sudha Garg; Michael A Nader
Journal:  Psychopharmacology (Berl)       Date:  2013-09-29       Impact factor: 4.530

5.  Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats.

Authors:  Ming Li; Radek Budin; Alison S Fleming; Shitij Kapur
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

Review 6.  Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.

Authors:  Tracy Swainston Harrison; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile.

Authors:  Jianyong Chen; Gregory T Collins; Jian Zhang; Chao-Yie Yang; Beth Levant; James Woods; Shaomeng Wang
Journal:  J Med Chem       Date:  2008-09-12       Impact factor: 7.446

8.  Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats.

Authors:  Danuta Marona-Lewicka; David E Nichols
Journal:  Psychopharmacology (Berl)       Date:  2003-11-28       Impact factor: 4.530

9.  Worsened hypertension control induced by aripiprazole.

Authors:  Norio Yasui-Furukori; Akira Fujii
Journal:  Neuropsychiatr Dis Treat       Date:  2013-04-15       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.